Bio-Techne Corp

Good morning, and welcome to the Biotechni Earnings Conference call for the fourth quarter of fiscal year 2024. At this time, all participants have been placed in a listen-only mode, and the call will be on question following management's prepared remarks. During our Q&A session, please limit yourself to one question and one follow-up. I would now like to turn the call over to David Clare, Biotechni's Vice President of Investor Relations.

Good morning, and thank you for joining us.

On the call with me this morning are Kim Kelderman, President and Chief Executive Officer, and Jim Hippel, Chief Financial Officer of Biotechnology. Before we begin, let me briefly cover our safe harbor statement. Some of the comments made during this conference call may be considered forward-looking statements, including beliefs and expectations about the company's future results. The company's 10-K for fiscal year 2023 identified certain factors that could cause the company's actual results to differ materially from those projected in the forward-looking statements made during this call. The company does not undertake to update any forward-looking statements because of any new information or future events or developments. The 10-K, as well as the company's other SEC filings, are available on the company's website within its investor relations section. During the call, non-GAAP financial measures may be used to provide information pertinent to ongoing business performance. Tables reconciling these measures to most comparable GAAP measures are available in the company's press release issued earlier this morning on the investor relations section of the Biotechnique Corporation website at www.bio-technique.com. Separately, in the coming weeks, we will be participating in the Morgan Stanley, Wells Fargo, and Baird conferences. We look forward to connecting with many of you at these upcoming events. I will now turn the call over to Kim. Thank you, Dave, and good morning, everyone.